214 related articles for article (PubMed ID: 12107236)
21. Mediation of the hepatic effects of growth hormone by its lipolytic activity.
Piatti PM; Monti LD; Caumo A; Conti M; Magni F; Galli-Kienle M; Fochesato E; Pizzini A; Baldi L; Valsecchi G; Pontiroli AE
J Clin Endocrinol Metab; 1999 May; 84(5):1658-63. PubMed ID: 10323396
[TBL] [Abstract][Full Text] [Related]
22. Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects.
Lanzi R; Manzoni MF; Andreotti AC; Malighetti ME; Bianchi E; Sereni LP; Caumo A; Luzi L; Pontiroli AE
J Clin Endocrinol Metab; 1997 Jul; 82(7):2239-43. PubMed ID: 9215300
[TBL] [Abstract][Full Text] [Related]
23. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
[TBL] [Abstract][Full Text] [Related]
24. Acute exposure to GH during exercise stimulates the turnover of free fatty acids in GH-deficient men.
Kanaley JA; Dall R; Møller N; Nielsen SC; Christiansen JS; Jensen MD; Jørgensen JO
J Appl Physiol (1985); 2004 Feb; 96(2):747-53. PubMed ID: 14594860
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat.
Vickers MH; Hofman PL; Gluckman PD; Lobie PE; Cutfield WS
Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1212-9. PubMed ID: 16803850
[TBL] [Abstract][Full Text] [Related]
26. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.
Vestergaard ET; Cichosz SL; Møller N; Jørgensen JOL; Fleischer J
Br J Clin Pharmacol; 2017 Dec; 83(12):2671-2677. PubMed ID: 28736944
[TBL] [Abstract][Full Text] [Related]
27. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
Alvarez P; Isidro L; Peinó R; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2003 Oct; 59(4):431-6. PubMed ID: 14510904
[TBL] [Abstract][Full Text] [Related]
28. Dose-response effects of free fatty acids on amino acid metabolism and ureagenesis.
Gormsen LC; Gjedsted J; Gjedde S; Nørrelund H; Christiansen JS; Schmitz O; Jørgensen JO; Møller N
Acta Physiol (Oxf); 2008 Mar; 192(3):369-79. PubMed ID: 17973949
[TBL] [Abstract][Full Text] [Related]
29. A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults.
Lucidi P; Lauteri M; Laureti S; Celleno R; Santoni S; Volpi E; Angeletti G; Santeusanio F; De Feo P
J Clin Endocrinol Metab; 1998 Feb; 83(2):353-7. PubMed ID: 9467540
[TBL] [Abstract][Full Text] [Related]
30. The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis.
Scacchi M; Orsini F; Cattaneo A; Grasso A; Filippini B; Pecori Giraldi F; Fatti LM; Moro M; Cavagnini F
Eur J Endocrinol; 2010 Aug; 163(2):201-6. PubMed ID: 20460421
[TBL] [Abstract][Full Text] [Related]
31. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women.
Burman P; Johansson AG; Siegbahn A; Vessby B; Karlsson FA
J Clin Endocrinol Metab; 1997 Feb; 82(2):550-5. PubMed ID: 9024252
[TBL] [Abstract][Full Text] [Related]
32. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
[TBL] [Abstract][Full Text] [Related]
33. Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency.
Filipsson Nyström H; Barbosa EJ; Nilsson AG; Norrman LL; Ragnarsson O; Johannsson G
J Clin Endocrinol Metab; 2012 Sep; 97(9):3185-95. PubMed ID: 22791760
[TBL] [Abstract][Full Text] [Related]
34. Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism.
Nørrelund H; Vahl N; Juul A; Møller N; Alberti KG; Skakkebaek NE; Christiansen JS; Jørgensen JO
J Clin Endocrinol Metab; 2000 May; 85(5):1912-7. PubMed ID: 10843174
[TBL] [Abstract][Full Text] [Related]
35. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
[TBL] [Abstract][Full Text] [Related]
36. Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects.
Andreotti AC; Lanzi R; Manzoni MF; Caumo A; Moreschi A; Pontiroli AE
Metabolism; 1994 Oct; 43(10):1207-13. PubMed ID: 7934970
[TBL] [Abstract][Full Text] [Related]
37. Growth hormone upregulates ANGPTL4 mRNA and suppresses lipoprotein lipase via fatty acids: Randomized experiments in human individuals.
Hjelholt AJ; Søndergaard E; Pedersen SB; Møller N; Jessen N; Jørgensen JOL
Metabolism; 2020 Apr; 105():154188. PubMed ID: 32084431
[TBL] [Abstract][Full Text] [Related]
38. Acipimox enhances spontaneous growth hormone secretion in obese women.
Kok P; Buijs MM; Kok SW; Van Ierssel IH; Frölich M; Roelfsema F; Voshol PJ; Meinders AE; Pijl H
Am J Physiol Regul Integr Comp Physiol; 2004 Apr; 286(4):R693-8. PubMed ID: 14670810
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism.
Mauras N; Martinez V; Rini A; Guevara-Aguirre J
J Clin Endocrinol Metab; 2000 Sep; 85(9):3036-42. PubMed ID: 10999782
[TBL] [Abstract][Full Text] [Related]
40. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials.
Maison P; Griffin S; Nicoue-Beglah M; Haddad N; Balkau B; Chanson P;
J Clin Endocrinol Metab; 2004 May; 89(5):2192-9. PubMed ID: 15126541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
